Eli Lilly And Co (NYSE:LLY) saw a significant decrease in short interest during the month of March. As of March 29th, there was short interest totalling 35,064,784 shares, a decrease of 73.7% from the March 15th total of 133,357,587 shares. Based on an average daily volume of 8,969,942 shares, the days-to-cover ratio is presently 3.9 days. Approximately 3.8% of the shares of the company are short sold.
In other news, SVP Alfonso G. Zulueta sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, January 31st. The stock was sold at an average price of $120.00, for a total transaction of $480,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 26th. The shares were sold at an average price of $131.41, for a total value of $26,939,050.00. Following the transaction, the insider now directly owns 116,814,018 shares of the company’s stock, valued at $15,350,530,105.38. The disclosure for this sale can be found here. Insiders have sold 989,224 shares of company stock valued at $123,587,253 over the last ninety days. Corporate insiders own 0.11% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in LLY. Athena Capital Advisors LLC acquired a new stake in Eli Lilly And Co in the fourth quarter worth approximately $26,000. Wakefield Asset Management LLLP acquired a new stake in Eli Lilly And Co in the fourth quarter worth approximately $27,000. Larson Financial Group LLC acquired a new stake in Eli Lilly And Co in the fourth quarter worth approximately $29,000. Ironwood Financial llc acquired a new stake in Eli Lilly And Co in the fourth quarter worth approximately $30,000. Finally, Trust Department MB Financial Bank N A lifted its position in Eli Lilly And Co by 54.7% in the first quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock worth $30,000 after purchasing an additional 82 shares during the period. Hedge funds and other institutional investors own 79.58% of the company’s stock.
Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). The business had revenue of $6.44 billion for the quarter, compared to analyst estimates of $6.28 billion. Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The business’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.14 earnings per share. On average, analysts predict that Eli Lilly And Co will post 5.66 earnings per share for the current year.
Several equities analysts have recently commented on the company. Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $142.00 target price for the company in a report on Wednesday, April 10th. Guggenheim lowered Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 target price for the company. in a report on Thursday, April 11th. Barclays reaffirmed a “buy” rating and set a $140.00 target price on shares of Eli Lilly And Co in a report on Sunday. Credit Suisse Group set a $121.00 target price on Eli Lilly And Co and gave the company a “hold” rating in a report on Friday, March 22nd. Finally, BMO Capital Markets reaffirmed a “buy” rating on shares of Eli Lilly And Co in a report on Wednesday, December 19th. Ten research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $118.02.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: Diversification
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.